A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2013
At a glance
- Drugs AVN 944; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Avalon Pharmaceuticals; Vertex Pharmaceuticals
- 03 Aug 2011 Planned end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 09 Jan 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 May 2008 The company is on track to complete this trial in 2008.